CIK 0001534969
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
SERA PROGNOSTICS, INC.
Sign in to watch- Ticker
- SERA
- Exchange
- Nasdaq
- Industry
- Services-Medical Laboratories
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 261911522
- Phone
- +1 801-990-0520
- Business address
- 2749 E. PARLEYS WAY, SUITE 200, SALT LAKE CITY, UT, 84109
- Former names
- SERA PROGNOSTICS, INC.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $79,563
- in 6 filings
Net −$79,563. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-06-03 | Kamdar Kim P. Director | Grant or award · Stock Option (right to buy) | +149,675 | 149,675 | ||
| 2022-06-03 | Mirza Mansoor Raza Director | Grant or award · Stock Option (right to buy) | +149,675 | 149,675 | ||
| 2022-06-03 | Phillips Joshua Director | Grant or award · Stock Option (right to buy) | +149,675 | 149,675 | ||
| 2022-06-01 | Boniface John J. Chief Scientific Officer | Exercise or conversion | +1,000 | $0.73 | $730 | 69,310 |
| 2022-06-01 | Boniface John J. Chief Scientific Officer | Sale | −1,000 | $1.36 | $1K | 68,310 |
| 2022-06-01 | Boniface John J. Chief Scientific Officer | Exercise or conversion · Stock Option (right to buy) | −1,000 | 2,844 | ||
| 2022-05-31 | Boniface John J. Chief Scientific Officer | Sale | −2,725 | $1.45 | $4K | 68,310 |
| 2022-05-24 | Boniface John J. Chief Scientific Officer | Sale | −2,725 | $1.54 | $4K | 71,035 |
| 2022-05-17 | Boniface John J. Chief Scientific Officer | Sale | −2,725 | $1.55 | $4K | 73,760 |
| 2022-05-10 | Boniface John J. Chief Scientific Officer | Sale | −2,725 | $1.97 | $5K | 76,485 |
| 2022-05-04 | Boniface John J. Chief Scientific Officer | Exercise or conversion | +1,000 | $0.73 | $730 | 80,210 |
| 2022-05-04 | Boniface John J. Chief Scientific Officer | Sale | −1,000 | $2.17 | $2K | 79,210 |
| 2022-05-04 | Boniface John J. Chief Scientific Officer | Exercise or conversion · Stock Option (right to buy) | −1,000 | 3,844 | ||
| 2022-05-03 | Boniface John J. Chief Scientific Officer | Sale | −2,725 | $2.17 | $6K | 79,210 |
| 2022-04-26 | Boniface John J. Chief Scientific Officer | Sale | −2,725 | $2.17 | $6K | 81,935 |
| 2022-04-19 | Boniface John J. Chief Scientific Officer | Sale | −2,725 | $2.08 | $6K | 84,660 |
| 2022-04-12 | Boniface John J. Chief Scientific Officer | Sale | −2,725 | $2.66 | $7K | 87,385 |
| 2022-04-11 | Barlow Jane F Director | Grant or award · Stock Option (right to buy) | +140,823 | 140,823 | ||
| 2022-04-06 | Boniface John J. Chief Scientific Officer | Exercise or conversion | +1,000 | $0.73 | $730 | 91,110 |
| 2022-04-06 | Boniface John J. Chief Scientific Officer | Sale | −1,000 | $3.02 | $3K | 90,110 |
Page 19 of 23 · 457 trades